1-(2,5-dimethoxyphenyl)-3-phenylthiourea is a **chemical compound** with the following structure:
[Image of 1-(2,5-dimethoxyphenyl)-3-phenylthiourea structure]
**Its importance lies in its potential applications in various research areas, including:**
* **Pharmacology:** This compound exhibits **anti-inflammatory** and **analgesic** properties. Research has shown it can effectively inhibit the production of inflammatory mediators, reducing pain and inflammation. This makes it a promising candidate for developing new drugs for treating inflammatory conditions.
* **Chemistry:** 1-(2,5-dimethoxyphenyl)-3-phenylthiourea serves as a **building block** for synthesizing other complex molecules with diverse biological activities. Its unique structure allows for various modifications and derivatization, opening up opportunities for developing new pharmaceuticals and materials.
* **Materials Science:** This compound exhibits **luminescent** properties, making it potentially useful in the development of **organic light-emitting diodes (OLEDs)** and other optoelectronic devices.
**However, it's important to note that research on this compound is still ongoing, and its potential therapeutic and technological applications are yet to be fully realized. Further studies are needed to understand its safety profile, pharmacokinetics, and long-term effects.**
**Additionally, it's crucial to consider the ethical and legal implications of researching and potentially utilizing this compound. Researchers must ensure adherence to all ethical guidelines and regulations.**
Overall, 1-(2,5-dimethoxyphenyl)-3-phenylthiourea represents a **promising molecule** with potential applications in multiple research fields. However, further research and development are necessary to fully understand its potential and explore its safe and effective use.
| ID Source | ID |
|---|---|
| PubMed CID | 730557 |
| CHEMBL ID | 1334348 |
| CHEBI ID | 107498 |
| SCHEMBL ID | 5450418 |
| Synonym |
|---|
| 32065-63-7 |
| nsc-213632 |
| nsc213632 |
| 1-(2,5-dimethoxy-phenyl)-3-phenyl-thiourea |
| OPREA1_248704 |
| smr000517062 |
| MLS001210693 |
| 1-(2,5-dimethoxyphenyl)-3-phenylthiourea |
| STK052198 |
| CHEBI:107498 |
| AKOS000487680 |
| HMS2843M21 |
| bdbm50448193 |
| CHEMBL1334348 , |
| SCHEMBL5450418 |
| DYIPNXQBWVUFEX-UHFFFAOYSA-N |
| n-(2,5-dimethoxyphenyl)-n'-phenylthiourea # |
| 1-(2,5-dimethoxyphenyl)-3-phenyl-thiourea |
| Q27185819 |
| 1-(2,5-dimethoxyphenyl)-3-phenyl-2-thiourea |
| n-(2,5-dimethoxyphenyl)-n'-phenylthiourea |
| DTXSID00953941 |
| n-(2,5-dimethoxyphenyl)-n'-phenylcarbamimidothioic acid |
| Class | Description |
|---|---|
| thioureas | Compounds of general formula RR'NC(=S)NR''R'''. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 39.8107 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 0.3162 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 19.9526 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Urease | Canavalia ensiformis (jack bean) | IC50 (µMol) | 29.9300 | 0.4570 | 3.2023 | 8.5900 | AID1071693 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 29.9300 | 0.0004 | 0.9086 | 10.0000 | AID1071693 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 29.9300 | 0.0003 | 0.3907 | 5.4000 | AID1071693 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 29.9300 | 0.0003 | 1.3833 | 8.4000 | AID1071693 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1071693 | Inhibition of jack bean urease using urea as substrate assessed as ammonia production after 15 mins by indophenol method | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and in vitro urease inhibitory activity of N,N'-disubstituted thioureas. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||